PMID- 16582045
OWN - NLM
STAT- MEDLINE
DCOM- 20060803
LR  - 20221207
IS  - 1064-7481 (Print)
IS  - 1064-7481 (Linking)
VI  - 14
IP  - 4
DP  - 2006 Apr
TI  - A double-blind, placebo-controlled study of venlafaxine and fluoxetine in 
      geriatric outpatients with major depression.
PG  - 361-70
AB  - BACKGROUND: Despite the high prevalence of depression in elderly patients, few 
      well-designed, placebo-controlled studies of antidepressants have been conducted 
      in this population. This masked, placebo-controlled trial assessed the efficacy 
      and safety of venlafaxine and fluoxetine in depressed patients older than 65 
      years. METHOD: Three hundred patients were randomly assigned to treatment with 
      venlafaxine immediate release ([IR]; N = 104), fluoxetine (N = 100), or placebo 
      (N = 96) in an eight-week trial. Venlafaxine doses were titrated from 37.5 to 225 
      mg per day and fluoxetine doses were titrated from 20 to 60 mg per day, as 
      necessary, over 29 days. Efficacy variables included the 21-item Hamilton 
      Depression Rating Scale (HAM-D21) total score, HAM-D21 depressed mood item score, 
      scores on the Montgomery Asberg Depression Rating Scale (MADRS), Clinical Global 
      Impression-Severity of Illness (CGI-S) and Improvement (CGI-I) scales, and rates 
      of response (based on change from baseline HAM-D or MADRS score or CGI-I score) 
      and remission (HAM-D17 < or =7). For the purposes of this report, efficacy 
      analyses are focused on the HAM-D21 total score. Safety assessments included 
      monitoring of adverse events (AEs), physical examinations, vital signs 
      assessments, laboratory determinations, and electrocardiograms. RESULTS: In all 
      three of the treatment groups, there was a significant reduction at week 8 
      compared with the baseline HAM-D21 total score. However, there were no 
      significant differences among the three treatment groups on the change in 
      HAM-D21, MADRS, or CGI scores from baseline to week 8. There was no statistically 
      significant difference in the proportion of remitters at the last on-therapy 
      visit. The incidence of individual AEs was higher in the venlafaxine group (27%) 
      compared with patients taking fluoxetine (19%) or placebo (9%). CONCLUSION: In 
      this study, there was no significant difference in efficacy among placebo, 
      venlafaxine, and fluoxetine for the treatment of depression.
FAU - Schatzberg, Alan
AU  - Schatzberg A
AD  - Stanford University School of Medicine, Stanford, CA 94605-5548, USA. 
      afschatz@leland.stanford.edu
FAU - Roose, Steven
AU  - Roose S
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Am J Geriatr Psychiatry
JT  - The American journal of geriatric psychiatry : official journal of the American 
      Association for Geriatric Psychiatry
JID - 9309609
RN  - 0 (Antidepressive Agents, Second-Generation)
RN  - 0 (Cyclohexanols)
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 01K63SUP8D (Fluoxetine)
RN  - 7D7RX5A8MO (Venlafaxine Hydrochloride)
SB  - IM
MH  - Aged
MH  - Ambulatory Care
MH  - Antidepressive Agents, Second-Generation/*therapeutic use
MH  - Cyclohexanols/*therapeutic use
MH  - Demography
MH  - Depressive Disorder, Major/diagnosis/*drug therapy/*psychology
MH  - Double-Blind Method
MH  - Female
MH  - Fluoxetine/*therapeutic use
MH  - Humans
MH  - Male
MH  - Selective Serotonin Reuptake Inhibitors/*therapeutic use
MH  - Severity of Illness Index
MH  - Surveys and Questionnaires
MH  - Venlafaxine Hydrochloride
EDAT- 2006/04/04 09:00
MHDA- 2006/08/04 09:00
CRDT- 2006/04/04 09:00
PHST- 2006/04/04 09:00 [pubmed]
PHST- 2006/08/04 09:00 [medline]
PHST- 2006/04/04 09:00 [entrez]
AID - S1064-7481(12)60685-X [pii]
AID - 10.1097/01.JGP.0000194645.70869.3b [doi]
PST - ppublish
SO  - Am J Geriatr Psychiatry. 2006 Apr;14(4):361-70. doi: 
      10.1097/01.JGP.0000194645.70869.3b.